SLC5A2 and diabetic kidney disease: As our understanding of SGLT2 inhibitors' role in DKD continues to evolve, ongoing research will likely focus on optimizing their use, identifying patient populations that benefit the most, and elucidating additional mechanisms contributing to renal protection.